Hybio Pharmaceutical Co., Ltd. (300199.SZ) Latest Company News

Oct 26, 2026, 11:20 UTC
Hanyu Pharmaceutical's wholly owned subsidiary Wuhan Hanyu plans to invest up to RMB 380 million to expand peptide-drug production lines, adding annual capacity of 10 tonnes when completed.
Source:
- finance.sina.cn
Oct 26, 2026, 11:18 UTC
Hanyu Pharmaceutical announced completion of a preclinical pharmacodynamic comparison study of HY3003 tablets for weight loss, reporting four-week weight reductions of about 11%, 26% and 47% in DIO mice and 3%, 11% and 31% in DIO rats.
Source:
- finance.sina.cn
Sep 10, 2026, 08:12 UTC
Hanyu Pharmaceutical received acceptance notices from China's National Medical Products Administration for clinical trial applications of HY3003 injection, developed with Shenzhen Tanyun Zhitai Pharmaceutical Technology for weight-loss indications.
Source:
- finance.sina.cn
Sep 7, 2026, 08:24 UTC
Hybio Pharmaceutical's subsidiary Gansu Chengji Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, a generic drug for treating postpartum hemorrhage, which will be launched for sale.
Source:
- finance.sina.cn
Aug 20, 2026, 12:29 UTC
Hybio Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 237 million yuan, up 62.72% year-on-year; revenue was 688 million yuan, up 25.27% year-on-year.
Source:
- finance.sina.cn
Aug 12, 2026, 13:20 UTC
Hanyu Pharmaceutical signed a cooperation agreement with Sansheng Mandi for semaglutide injection (blood glucose control indication).
Source:
- finance.ifeng.com
Aug 12, 2026, 10:26 UTC
Hybio Pharmaceutical signed a cooperation agreement with Sansheng Mandi regarding semaglutide injection.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 7, 2026, 08:40 UTC
Hybio Pharmaceutical announced that its first generic filing for the tirzepatide injection has been accepted by the National Medical Products Administration, becoming the first domestic company to submit such an application.
Source:
- finance.sina.cn
Jul 29, 2026, 10:05 UTC
HanYu Pharmaceutical announced that its new GLP-1/GIP/GCGR triple receptor agonist HY3003 injection has completed preclinical animal pharmacodynamic studies.
Source:
- finance.sina.cn
Jul 6, 2026, 11:10 UTC
Han Yu Pharmaceutical's wholly-owned subsidiary Han Yu Pharmaceutical (Wuhan) Co., Ltd. received approval from the National Medical Products Administration for the marketing of its chemical active pharmaceutical ingredient liraglutide (H).
Source:
- finance.sina.cn
Jul 3, 2026, 08:52 UTC
The China National Medical Products Administration's Drug Evaluation Center accepted the marketing authorization application for semaglutide injection (weight loss indication) filed by Sansheng Mandi, a partner of Hybio Pharmaceutical.
Source:
- finance.sina.cn

300199.SZ

Hanyu Pharmaceutical's wholly owned subsidiary Wuhan Hanyu plans to invest up to RMB 380 million to expand peptide-drug production lines, adding annual capacity of 10 tonnes when completed.

Hanyu Pharmaceutical announced completion of a preclinical pharmacodynamic comparison study of HY3003 tablets for weight loss, reporting four-week weight reductions of about 11%, 26% and 47% in DIO mice and 3%, 11% and 31% in DIO rats.

Hanyu Pharmaceutical received acceptance notices from China's National Medical Products Administration for clinical trial applications of HY3003 injection, developed with Shenzhen Tanyun Zhitai Pharmaceutical Technology for weight-loss indications.

Hybio Pharmaceutical's subsidiary Gansu Chengji Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, a generic drug for treating postpartum hemorrhage, which will be launched for sale.

Hybio Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 237 million yuan, up 62.72% year-on-year; revenue was 688 million yuan, up 25.27% year-on-year.

Hanyu Pharmaceutical signed a cooperation agreement with Sansheng Mandi for semaglutide injection (blood glucose control indication).

Hybio Pharmaceutical signed a cooperation agreement with Sansheng Mandi regarding semaglutide injection.

Hybio Pharmaceutical announced that its first generic filing for the tirzepatide injection has been accepted by the National Medical Products Administration, becoming the first domestic company to submit such an application.

HanYu Pharmaceutical announced that its new GLP-1/GIP/GCGR triple receptor agonist HY3003 injection has completed preclinical animal pharmacodynamic studies.

Han Yu Pharmaceutical's wholly-owned subsidiary Han Yu Pharmaceutical (Wuhan) Co., Ltd. received approval from the National Medical Products Administration for the marketing of its chemical active pharmaceutical ingredient liraglutide (H).

The China National Medical Products Administration's Drug Evaluation Center accepted the marketing authorization application for semaglutide injection (weight loss indication) filed by Sansheng Mandi, a partner of Hybio Pharmaceutical.